VKTX — Viking Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$32.88
-$0.80 (-2.36%)
Viking Therapeutics Inc (VKTX) is a biotechnology company listed on NASDAQ. It is led by Brian Lian Ph.D., based in 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121, with about 65 employees. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Latest reported VKTX revenue for 2025-09-30 was $0. Net income was -$202.0M. VKTX currently screens at market cap $3.97B.
Use this VKTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VKTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VKTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Viking Therapeutics Inc even when a live quote feed is slow.
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Key Statistics
Market Cap
$3.97B
Volume
2.07M
Previous Close
$33.23
Day Range
$33.43 – $34.99
EPS
-$1.01
Revenue
$0.00
Net Income
-$109.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
65
VKTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$109.96M | -$85.89M | -$68.87M | -$54.99M |
| EPS (Diluted) | -$1.01 | -$0.91 | -$0.90 | -$0.71 |
Total Assets
$908.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$26.68M
Operating Cash Flow
-$87.79M
Free Cash Flow
$0.00
Viking Therapeutics Inc Company Information
- President, CEO & Director
- Brian Lian Ph.D.
- Headquarters
- 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
- Website
- www.vikingtherapeutics.com
- Phone
- 858 704 4660
- IPO / Founded
- 2015-04-29
- Sector
- Healthcare
- Industry
- Biotechnology